Domestic price of Ramucirumab

Ramucirumab is a human VEGFR2 antagonist. It is a recombinant human IgG1 monoclonal antibody produced in genetically engineered mammalian NS0 cells. Unlike other drugs targeting VEGFR-2, ramucizumab binds to a specific epitope on the extracellular domain of VEGFR-2, thereby blocking the binding of all VEGF ligands to it.

The first drug approved by the U.S. Food and Drug Administration (FDA) for the second-line treatment of patients with advanced or metastatic gastric cancer or GEJ adenocarcinoma. It can be used as a monotherapy (Category 1) or in combination with paclitaxel (Category 2A). The approval is based on evidence of improved overall survival and progression-free survival in multinational, randomized, double-blind, placebo-controlled studies. Subsequently, ramucirumab was approved for the treatment of metastatic non-small cell lung cancer, metastatic colorectal cancer, and hepatocellular carcinoma. The most common adverse reactions observed in patients receiving ramucirumab were hypertension and diarrhea.

Ramosizumab is usually an injection preparation. The original drug has been on the market in China, but it has been on the market for a short time and has not been included in the medical insurance. The price of 100mg/10mL per box may be around RMB 5,000, and the price of 500mg/50mL per box may be around RMB 17,000. The price of the original Hong Kong version of 100mg/10mL may be around RMB 8,400 per box, and the price of 500mg/50mL per box may be around RMB 28,000 (the price may fluctuate due to exchange rates), and their pharmaceutical ingredients are basically the same. Currently, there are no generic drugs produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.